期刊
FEBS JOURNAL
卷 280, 期 15, 页码 3563-3575出版社
WILEY
DOI: 10.1111/febs.12298
关键词
ADP-ribosyltransferases; cancer; drug design; PARP; poly(ADP-ribose) polymerases; polypharmacology; promiscuity; selective inhibitors; selectivity; structure-based drug design
Inhibition of ADP-ribosyltransferases with diphtheria toxin homology (ARTD), widely known as the poly(ADP-ribose) polymerase (PARP) family, is a strategy under development for treatment of various conditions, including cancers and ischemia. Here, we give a brief summary of ARTD enzyme functions and the implications for their potential as therapeutic targets. We present an overview of the PARP inhibitors that have been used in clinical trials. Finally, we summarize recent insights from structural biology, and discuss the molecular aspects of PARP inhibitors in terms of broad-range versus selective inhibition of ARTD family enzymes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据